HAPLOIDENTICAL STEM CELL TRANSPLANTATION
Clinical trials for HAPLOIDENTICAL STEM CELL TRANSPLANTATION explained in plain language.
Never miss a new study
Get alerted when new HAPLOIDENTICAL STEM CELL TRANSPLANTATION trials appear
Sign up with your email to follow new studies for HAPLOIDENTICAL STEM CELL TRANSPLANTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a cancer drug make stem cell transplants safer for sickle cell patients?
Disease control Recruiting nowThis study tests whether adding the drug ruxolitinib to a standard stem cell transplant can prevent graft failure in children and young adults with severe sickle cell disease. Up to 24 participants will receive the drug during conditioning and be followed for two years after tran…
Matched conditions: HAPLOIDENTICAL STEM CELL TRANSPLANTATION
Phase: PHASE1, PHASE2 • Sponsor: Arkansas Children's Hospital Research Institute • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug aims to stop immune attack after stem cell transplants
Disease control Recruiting nowThis study tests a drug called BPC2001 to prevent acute graft-versus-host disease (aGVHD), a serious complication where donor immune cells attack the patient's body after a stem cell transplant. Fifty adults with blood cancers like leukemia will receive six weekly doses of BPC200…
Matched conditions: HAPLOIDENTICAL STEM CELL TRANSPLANTATION
Phase: PHASE2 • Sponsor: BioPhoenix Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC